GlassScriptPhysician profile
Gavin P Hart
NPI 1033434535
$93,880.09
in general payments reported to CMS, 2019-2025
9 companies · $11K in 2025
The $11K reported for 2025 was more than what 88% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,640 · 2020: $6,256 · 2021: $5,019 · 2022: $1,417 · 2023: $32K · 2024: $36K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $74K · Food and Beverage: $3,685 · Travel and Lodging: $2,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $73,583.61 |
| Food and Beverage | $3,684.68 |
| Travel and Lodging | $2,280.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $83,555.95 | 2019-2025 | Pinnacle, Actis, Attune |
| Stryker Corporation | $7,546.79 | 2019-2025 | Insignia, Mako, Trident |
| Kyocera Medical Technologies, INC. | $1,725.69 | 2019-2023 | |
| Depuy Synthes Sales INC. | $787.17 | 2022-2025 | Attune, Monovisc, Tfn-Advance |
| Exactech, INC. | $157.91 | 2019 | |
| Smith+Nephew, INC. | $56.05 | 2019 | |
| Bioventus LLC | $19.40 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $16.41 | 2025 | Exparel |
| Vericel Corporation | $14.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gavin Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.